Compare CRNX & GFF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRNX | GFF |
|---|---|---|
| Founded | 2008 | 1959 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Building Products |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 4.1B |
| IPO Year | 2018 | 1994 |
| Metric | CRNX | GFF |
|---|---|---|
| Price | $41.08 | $91.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 3 |
| Target Price | $76.75 | ★ $105.00 |
| AVG Volume (30 Days) | ★ 968.2K | 364.5K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 0.99% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.41 |
| Revenue | $1,039,000.00 | ★ $2,519,926,000.00 |
| Revenue This Year | $720.10 | N/A |
| Revenue Next Year | $184.67 | N/A |
| P/E Ratio | ★ N/A | $64.60 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $25.83 | $65.01 |
| 52 Week High | $57.99 | $97.58 |
| Indicator | CRNX | GFF |
|---|---|---|
| Relative Strength Index (RSI) | 60.96 | 64.96 |
| Support Level | $39.88 | $73.09 |
| Resistance Level | $41.33 | $96.39 |
| Average True Range (ATR) | 1.52 | 3.05 |
| MACD | 0.27 | -0.01 |
| Stochastic Oscillator | 76.34 | 84.59 |
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
Griffon Corp manufactures and markets residential, commercial and industrial garage doors to professional installing dealers and home center retail chains. It also provides non-powered landscaping products for homeowners and professionals. Its operating segments include Consumer and Professional Products: is a provider of branded consumer and professional tools; residential, industrial and commercial fans; home storage and organization products; and Home and Building Products conducts its operations through Clopay Corporation (Clopay). Clopay is the manufacturer and marketer of garage doors and rolling steel doors in North America. The company generates a majority of its revenue from the Home and Building Products segment. Operates in USA, Europe, Canada, Australia, and Others.